End-to-End Machine Learning-Driven Design of Targeted Monoclonal Antibodies

Described herein are techniques for designing proteins for binding to a target. In some embodiments, the techniques include: obtaining an amino acid sequence for a candidate protein that binds to the target with a candidate binding affinity; determining, for proteins in a set of proteins, probabilities that the binding affinities between the proteins and the target are greater than the candidate binding affinity, and identifying a subset of the set of proteins based on the determined probabilities. Determining a first probability that a first binding affinity between a first protein and the target is greater than the candidate biding affinity may include: processing a first amin acid sequence of the first protein using a trained machine learning model to obtain a first output indicative of the first binding affinity; and determining the first probability using the first output indicative of the first binding affinity between the first protein and the target. 

Researchers

Matthew Walsh / Rajmonda Caceres / Rafael Jaimes / Lin Li / Esther Wolf / Will Spaeth / Leslie Shing / Tristan Bepler

Departments: Lincoln Laboratory
Technology Areas: Artificial Intelligence (AI) and Machine Learning (ML) / Drug Discovery and Research Tools: Antibodies / Therapeutics: Proteins & Antibodies
Impact Areas: Healthy Living

  • end-to-end machine learning-driven design of proteins
    Singapore | Published application
  • end-to-end machine learning-driven design of proteins
    Singapore | Pending
  • end-to-end machine learning-driven design of proteins
    United States of America | Pending

License this technology

Interested in this technology? Connect with our experienced licensing team to initiate the process.

Sign up for technology updates

Sign up now to receive the latest updates on cutting-edge technologies and innovations.